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ABSTRACT
Objectives: To investigate the feasibility of using
research papers cited in clinical guidelines as a way to
track the impact of particular funding streams or
sources.
Setting: In recent years, medical research funders
have made efforts to enhance the understanding of the
impact of their funded research and to provide
evidence of the ‘value’ of investments in particular
areas of research. One of the most challenging areas of
research evaluation is around impact on policy and
practice. In the UK, the National Institute of Health and
Clinical Excellence (NICE) provide clinical guidelines,
which bring together current high-quality evidence on
the diagnosis and treatment of clinical problems.
Research referenced in these guidelines is an
indication of its potential to have real impact on health
policy and practice.
Design: This study is based on analysis of the
authorship and funding attribution of research cited in
two NICE clinical guidelines: dementia and chronic
obstructive pulmonary disease.
Results: Analysis identiﬁed that around a third of papers
cited in the two NICE guidelines had at least one author
based in the UK. In both cases, about half of these UK
attributed papers contained acknowledgements which
allowed the source of funding for the research to be
identiﬁed. The research cited in these guidelines was
found to have been supported by a diverse set of
funders from different sectors. The study also
investigated the contribution of research groups based
in universities, industry and the public sector.
Conclusions: The study found that there is great
potential for guidelines to be used as sources of
information on the quality of the research used in their
development and that it is possible to track the source
of the funding of the research. The challenge is in
harnessing the relevant information to track this in an
efﬁcient way.
INTRODUCTION
Medical research has advanced rapidly in
recent times in all areas from basic sciences
(ie, decoding the human genome) to the
development of more precise diagnostic tools
and novel treatments. At the same time,
public interest in biomedical advances and
the appetite for more effective treatments
1 are
increasing in parallel. The demand for the
results of biomedical research to lead to
improvement in healthcare has never been
higher.
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ARTICLE SUMMARY
Article focus
- Explore the feasibility of extracting the funding
source of research papers cited in clinical
guidelines.
- Identify who funded the research which supports
the guideline development.
- Investigate the shared characteristics of the
publications cited in the two guidelines chosen
for the study (dementia and chronic obstructive
pulmonary disease).
Key messages
- Looking at citation in clinical guidelines could
potentially be used as one of the tools in the
impact evaluators toolkit.
- For this methodology to be fully exploited, the
accessibility of data and acknowledgement of
funders in articles need to be improved.
- This study helps to investigate the connection
between funding inputs with changes in medical
practice and the pathways for these to arise.
Strengths and limitations of this study
- An assumption is made that the fact that
a research article is cited in a clinical guideline
is a proxy for potential impact; however, this
impact is not proven in this study.
- The methodology relies on the correct and full
attribution of funders in research articles;
however, evidence shows that this information
can be incomplete.
- NICE guidelines are very closely linked with the
National Health Service in the UK, as such this
limits actual results of the study, but the
methodology could be applied to other similar
documents.
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Open Access ResearchAcross the research world, and particularly in the
biosciences, there has been a drive to better demonstrate
and understand the impacts of research, essentially so
that funds can be allocated to maximum effect.
1 There
remains a concern that the research community as
a whole could be better at translating the ﬁndings of
medical research into tangible health and healthcare
beneﬁts.
5e7 Thus, the need to better understand
research impact and in particular the pathways to that
impact is a key priority for research funders.
8e11
However, determining the impact of research is chal-
lenging, particularly in basic and fundamental research
where the time lag between original research and
subsequent impacts on health can be long and the
attribution difﬁcult to track. In addition, perhaps one of
the most challenging areas has been trying to under-
stand the nature of the pathways to and subsequent
impact of research on policy and practice.
National and international clinical guidelines are
intended to bring together the best and most current
evidence about the prevention, diagnosis, prognosis
and therapy of clinical problems. Clinical guidelines
are a form of systematic review and, in the UK, focus on
the deﬁned medical needs of the National Health
Service (NHS). It should be noted that clinical guide-
lines are not standards of care but are recommenda-
tions to the non-specialist or general practitioner. In
the UK, clinical guidelines are provided by the National
Institute for Health and Clinical Excellence (NICE),
12
and since 2005, these have had legal standing in the
NHS in England and Wales. As such, the results of
this particular study are potentially limited to the
NHS; however, the methodology could possibly be
applied to guidelines governed by other bodies. The
guidelines exist to help standardise and improve
patient care and can help to introduce cost-efﬁciencies
to the delivery of healthcare. The guidelines are
evidence based and their formulation brings pieces of
important and inﬂuential research together. For
a funder, if research it has supported is referenced as
part of the evidence supporting a national and/or
international clinical guideline, then it is an indication
that this research is likely to be inﬂuencing policy and
practice. Hence, clinical guidelines are potentially an
attractive resource to support impact tracking and
assessment.
13 14
For those engaged in evaluation, historically it has
been difﬁcult to extract information from a guideline in
a way that helps support analysis of the references and
funding sources: simply put, UK clinical guidelines are
not designed to support the requirements of funders
trying to track the impact of their support. However,
work is underway at the US National Center for
Biotechnology Information (part of the National Library
of Medicine, National Institutes of Health) to digitise the
content of major international clinical guidelines to
encourage wider access to their content and enable
greater ability to mine their content and allow auto-
mated links to individual cited research papers via
databases such as PubMed.
In 2009, the UK Medical Research Council, the Well-
come Trust and the National Institute for Health
Research, who among them commit nearly £2bn annu-
ally to support biomedical and applied health research,
commissioned a detailed analysis of the research cited
on a small number of UK clinical guidelines to explore
the potential of the information in broader research
impact tracking. The objectives of this research were
threefold. First, this study explored the feasibility of
extracting the funding source of the research papers cited
on a guideline. Second, it identiﬁed who funded the
research cited in the selected clinical guidelines. Third,
it explored the extent to which there are shared charac-
teristics of the publications cited in these guidelines.
The then-current NICE guidelines for the manage-
ment and treatment of two disease areas were selected:
dementia (2006) and chronic obstructive pulmonary
disease (COPD) (2004).
15 16 These guidelines were of
interest for the purposes of this analysis since (1) they
had been available unchanged for several years and (2)
there was a likelihood that all three project sponsor
funders would have funded some of the underlying
research evidenced in the guidelines. The two guidelines
were also in quite different clinical areas, so the authors
wanted to see if there were differences in the process
and/or adoption of research into practice. For each
guideline, all cited research was examined to pick out its
characteristics (eg, age, bibliometric indicators) and
identify any funding attributions.
METHODS
Data extraction
The ﬁrst step was to extract a list of publications from
each of the guidelines and export them into a Microsoft
Excel spreadsheet. This was performed automatically
using bespoke RAND Europe computer scripts, based on
the PERL scripting language. Here, we brieﬂy describe
the methodology since a full description is available
elsewhere.
17 A total of 744 references were extracted
from the dementia guideline and 446 from the COPD
guideline.
Data cleaning
The extracted bibliographic references were cleaned
and structured to permit analyses of funding source and
paper performance indicators. Any references identiﬁed
as non-academic or peer-reviewed publications (eg,
references to a website, grey literature) and all publica-
tions before 1980 were removed since these could not be
investigated using the Web of Science.
After extraction and initial cleaning, a total of 616
references were found for the dementia guideline
(79.4% of the original 776 references) and 412 refer-
ences for the COPD guideline (83.9% of the original 491
references).
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Tracking the impact of research on policy and practiceData processing
For the funding analyses, the extracted publications
were searched for in Web of Science
18 to ﬁnd the insti-
tution and country afﬁliations of the authors listed. One
aim was to identify the publications with at least one UK
author on the assumption that this would facilitate
further funding analysis. Another aim was to use all the
extracted publications for further bibliometric analysis
(see Grant et al
19 for a similar methodology).
From the dementia guideline, 494 of the 616 extracted
publications (80.1%) were found in the Web of Science.
While from the COPD guideline, 335 of 412 publications
were available (81.3%). Any publications not found in
the Web of Science were processed individually through
a search methodology utilising the publication libraries
of RAND Europe and Cambridge University. All search
processes were duplicated by a second researcher to
eliminate errors.
This methodology used a simple search of both the
RAND library by article title, using Google Scholar and
the Cambridge University online library and free access
journals, through the Google search engine. If the
author afﬁliation and country remained unidentiﬁed,
then the RAND library was searched by journal,
followed by browsing for the article using the reference
data available. In addition, the title could be searched
for by keyword within the journal. Finally, where
possible, Cambridge University print holdings were
searched to ﬁnd any articles that were not accessible
online.
FUNDER ACKNOWLEDGEMENT
Where publications had at least partial UK attribution,
the funding source was searched for in the Research
Outputs Database.
20 21 This is a database housed at the
Wellcome Trust recording the funding sources for UK
and Irish publications in the biomedical sciences for the
period 1988e2001. Funding acknowledgements were
found for around one-third of publications using this
database. For the remaining publications, which fell
outside of the appropriate date range or were not found
in the Research Outputs Database, the full text of the
publication was found and funding acknowledgements
recorded directly, where available.
Funding source references were then standardised and
categorised by broad sector. UK funders acknowledged
on cited papers were categorised into the following
categories: industry, not-for-proﬁt, hospital trust, govern-
ment department, government agency (not controlled by
ministries), local or regional authority, foundation, none
given and unknown.
BIBLIOMETRIC AND PAPER CHARACTERISTIC ANALYSIS
Author afﬁliations and country locations were identiﬁed
for 595 of the 616 (97%) dementia guideline publica-
tions and 402 of the 412 (98%) COPD guideline publi-
cations. These afﬁliated papers form the basis of the
following descriptive and bibliometric analysis.
The citation impact of the publications referenced in
both clinical guidelines was analysed by sector using the
concept of citation proﬁling. This is based on a normal-
ising technique called ReBased Impact (RBI), which
takes account of the ﬁeld in which a paper appears and
the date since its publication to effectively provide
a proxy measure for the ‘quality’ of each paper. The
world average RBI is 1; the most highly cited articles have
an RBI >8.
22
Whole counts were used throughout this analysis; if
more than one funding source is cited in a publication,
this was recorded as one publication for each funding
source.
RESULTS
Attribution by funding organisation
In a large proportion of cited papers, no funding
acknowledgement was listed.
Nearly half (104 of the 228; 46%) of publications in
the dementia guideline with a UK author did not
acknowledge any funder. Funding information was
available for 117 papers, with the full text of seven papers
inaccessible and, hence, missing the funding informa-
tion. For the 148 publications in the COPD guideline
with at least one UK author, 60 included no funding
acknowledgement (41%). Funding information was
available for 81 publications. The full text of seven
publications was not accessible and therefore no funding
data were available.
Examination of the funding acknowledgements for
the Medical Research Council, the Department of
Health (England), the NHS and the Wellcome Trust
revealed that these funders were overtly linked to only
a small proportion of papers cited in the guidelines
(see ﬁgure 1dnumbers of publications by funding
source).
Attributions by funding organisation over time
To determine whether the practice of acknowledgement
of funding has improved over time, funding acknowl-
edgement was analysed by year of publication. Although
Figure 1 Numbers of publications by funding source.
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Tracking the impact of research on policy and practiceit appears that more recent publications have more
complete funding acknowledgements than older ones,
over the whole period, and for both guidelines, there
was no clear statistical relationship between the age of
publication and the presence or absence of a funding
acknowledgement (see ﬁgure 2dfunding acknowledge-
ment by year).
The clinical guidelines, on the whole, cited recent
research; the majority of research papers cited in these
two UK clinical guidelines were published after 2000,
that is, within 5 years of the release of these guidelines.
The average duration between the publication date of
papers cited and the publication date of the citing
guideline was 5 years for dementia and 3 years for
COPD.
Attribution by funding sector
Industry was not as prominent a funding source for
publications cited in the dementia guideline, where
acknowledgements were distributed across a range of
funding sources across sectors. In the COPD guideline,
industry was the most frequently linked funder after
‘none given’.
Attribution by country
Of the 616 publications extracted from the dementia
guideline, 228 (37.2%) had at least one UK-based
author, while from the COPD guideline, 148 publica-
tions (35.9%) had at least one UK-based author.
Researchers based in the UK and USA combined were
linked to the majority of papers cited in both guidelines.
Despite dominance of the UK and USA-based
researchers in the cited papers, many other countries
contributed to these publications. Papers cited in the
dementia and COPD guidelines were linked to authors
from 37 and 36 countries, respectively (see ﬁgure 3d
contribution of the most active countries).
Attribution by research sector
The three research funders use different means of
disbursing their money. Funding includes grants to
universities and hospitals, alongside direct support for
intramural research. Publication analysis by associated
institutions revealed that researchers with university
addresses, followed by those with hospital addresses,
were linked to the bulk of papers cited on both guide-
lines. More than 80% of publications cited in the two
guidelines involved authors based at universities. The
scientiﬁc contribution from other types of publicly
funded institutions, as well as from non-proﬁt institu-
tions, was low.
Nearly 20% of the publications cited in the COPD
guideline involved authors from industryda slightly
higher proportion than in the Dementia guideline.
Citation quality
Clinical guideline drafting committees are obliged to
base their recommendations on the ‘best’ research
available. The citation impact of the publications
Figure 2 Funding acknowledgement by year.
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Tracking the impact of research on policy and practicereferenced in both clinical guidelines was analysed by
sector using the concept of citation proﬁling.
Overall, papers cited across both guidelines had high
RBIs. Papers linked to universities, companies (industry)
and publicly funded research institutions were particu-
larly highly cited. At the time of the analysis, for the
COPD guideline, cited papers linked to publicly funded
research institutions had RBI>8; for the dementia
guideline, papers linked to universities, companies and
publicly funded research institutions all had particularly
impressive RBIs (see ﬁgure 4dcitation score by institu-
tional sector).
DISCUSSION
Funding attribution
Perhaps the greatest challenge in research impact
assessment is dealing with attribution. Attribution of
research outcomes and impacts to a speciﬁc funder is
complex and, in many cases, improbable. This arises
from most medical research receiving funding from
multiple sources, involving a host of researchers (often
across institutions) and being incremental such that
considerable time elapses between original research and
impact on health. The tide has turned on this issue and
funding bodies are increasingly working together to
identify where their funding has made a difference and
contributed to an outcome or impact. Exclusively
‘claiming’ impact ignores the complexities and reality of
scientiﬁc research and we are more interested in noting
our contribution alongside others and learning from
this.
Nevertheless, there is much we can do to help us
better understand the connection between funding
inputs and changes in medical practice. This research
project was intended to ﬂesh out some of the issues that
we face in trying to link research funding to research
output (ie, research papers) and speciﬁc outcomes
(clinical guidelines).
Figure 3 Contribution of the
most active countries.
Figure 4 Citation score by
institutional sector.
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Tracking the impact of research on policy and practiceAs described, there was some variability in the quality of
acknowledgement information provided on papers. In
our analysis, we did not explore whether the differences
in acknowledgement quality and completeness varied
according to the nature of the paper (ie, underpinning vs
more applied research). A study of 43 UK clinical
guidelines (and associated Health Technology Assess-
ments) related to cancer demonstrated that the number
of funding sources acknowledged in papers varied with
the ‘basicness’ of the publications: the more clinical
papers have “fewer (funding) sources and the more basic
papers have more.”
13
An interesting direction for future research work on
clinical guidelines would be to investigate whether the
high proportion of cited publications with at least one
UK author in the UK clinical guidelines could be the
result of a speciﬁc funding strategy. That is, some
research could be being funded to help create evidence
for the development of clinical guidelines. This speciﬁc
funding strategy might explain partially why UK-auth-
ored publications are over-cited in the UK guidelines,
relative to the share of publications.
The advice given to funding recipients by UK funders
regarding how they should be acknowledged in publi-
cations, and the extent to which these requirements
have been enforced, has varied signiﬁcantly over the
last two decades. While most funders have included a
requirement for acknowledgement in their terms
and conditions of award, it has only been since 2008
that there has been published guidance about a stan-
dard format.
23 T h i sm a ye x p l a i nw h yi n d u s t r yi sf a i r l y
highly cited across both guidelines as part of
a researcher’s more stringent contractual obligations.
However, it is worth noting that the extent to which
researchers are following the standard format is
unknown. Furthermore, the reality remains that, given
the incremental nature of much research, it is not easy
to precisely attribute a publication to its source of
funding.
One broader question is how to ensure that research
information is accessible in order to avoid spending
funds on research that either cannot be used or may be
duplication.
24
Temporal issues
We did ﬁnd a correlation between the publication of the
clinical guidelines and the dates of the papers cited
within it. These results corroborate earlier research.
13
Other bibliometric studies on UK clinical guidelines also
found that a signiﬁcant share of publications cited are
published within the 10 years prior to the release of
these guidelines.
19 25
Therefore, this ﬁnding was not unexpected, since
clinical guidelines should be based on new evidence,
although on occasion the newest evidence may not be
the best. However, it would be interesting to investigate
whether the most recent publications cited are the
outcome of research speciﬁcally funded to support the
development of a clinical guideline, thus potentially
explaining the peak in publications cited in the two
guidelines a few years before their release.
National contributions
The UK’s contribution is high in both guidelines, since
its world share in medical research measured by its share
in the total number of publications published in the
ﬁeld amounted to approximately 8.6% in 2006.
26 This
high proportion of papers linked to UK-based authors
echoes the ﬁnding of previous studies. Interestingly, our
analysisdwhere around a third of papers are linked to
UK-based authorsdreveals a higher proportion than we
have seen in other analyses.
CONCLUSIONS AND RECOMMENDATIONS
Having greater access to the work cited on clinical
guidelines would present new opportunities for funders
and the research community alike to better understand
some of the mechanisms that take research from the
laboratory to the bedside. While this would be but one
tool in the research impact evaluator’s toolkit, it would be
one that could be relatively easy to harness if both access
and acknowledgements were improved. As described,
work is underway between the UK NICE and the National
Center for Biotechnology Information, and in the future,
it is envisioned that other guideline providers will make
their content available in much more structured and
accessible formats to permit analyses of this nature.
However, to bring clarity to the tracking of research
inputs through to published output, the age-old problem
of ensuring accurate and complete acknowledgement
information on peer-reviewed published work needs to
be addressed. This requires a change in the culture of
how researchers use acknowledgements and greater
liaison with publishers and information providers who
could do much to enhance the quality and completeness
of funding data as a paper is submitted for publication.
Clarity and perhaps demarcation between the require-
ments of an ‘acknowledgement’ section on a paper and
description of the ‘funding’ that has supported the work
would seem an easy step to help remedy this.
27 This is
particularly pertinent as information providers such as
Thomson Reuters and Elsevier are now developing
complex reporting and analytical tools that provide an
ability to scrutinise the characteristics of published
workdincluding who is described as funding the
workdin new and exciting ways.
Furthermore, if the methodology of this paper is to be
generalised both beyond formal guidelines and to other
healthcare delivery and research output systems and
metrics, then novel methods of identifying and tracking
researchers and their outputs, via global identiﬁer
systems such as that proposed by the ORCID
28 (Open
Researcher and Contributor ID) initiative, will be
important.
Moves to address the deﬁnition of an ‘acknowledge-
ment’ may also help to address the issue of ‘over-
authorship’ and author inﬂation that has been seen in
recent years. This is thought to be fuelled in part by the
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Tracking the impact of research on policy and practicedrive towards impact assessment through national
research allocation formulae, such as the UK Research
Excellence Framework.
29 Some contributors listed as
‘authors’ might be more appropriately ‘thanked’. Many
journals now contain a section that asks for a description
of ‘contributions’dthese often do not contain all those
listed in the author list so there may be a place for
a more deﬁned ‘acknowledgement as thanks’ section.
Funders should also ensure clarity around their
requirements for a ‘funding acknowledgement’.
Complexities arise, for example, when research takes
place in buildings funded by a speciﬁc donor or when
a speciﬁc piece of research uses a piece of equipment
funded by a speciﬁc donor. And for how long after
funding has been received by a researcher should they
continue to provide a funding acknowledgement?
We found that there is great potential for national and
international guidelines to be used as sources of infor-
mation to help further our understanding on the impact
of research on practice; the challenge is to be able to
harness that information in an efﬁcient waydso that we
are able to use this information to feed into future
research strategy and thereby make the research cycle
more effective.
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